ProCE Banner Activity

Answering the Questions on Switching ART With Virologic Suppression

Podcast Episodes
Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.

Released: October 19, 2022

Expiration: October 18, 2023

No longer available for credit.

Share

Faculty

Tristan J. Barber

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP: consultant/advisor/speaker: Gilead Sciences, Merck, Roche, Theratechnologies, ViiV Healthcare; researcher: Roche, ViiV Healthcare; unrestricted educational grant holder: Gilead Sciences.

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant financial relationships to disclose.